Methods and compositions for treating tumours, especially skin tumours, by locally administering single doses of tumour necrosis factor alpha (TNFa) and interleukin-2 (IL2) at the tumour site, where the TNFa and IL2 are delivered as immunoconjugates comprising an antibody targeted to a splice isoform of an extracellular matrix component such as fibronectin.